These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22874771)

  • 21. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.
    Mao L; Si L; Chi Z; Cui C; Sheng X; Li S; Tang B; Guo J
    Eur J Cancer; 2011 Jul; 47(10):1498-503. PubMed ID: 21493058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role interferon-alpha in malignant melanoma remains to be defined.
    Eggermont AM
    Eur J Cancer; 2001 Nov; 37(17):2147-53. PubMed ID: 11677100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant Therapy for Melanoma.
    Agha A; Tarhini AA
    Curr Oncol Rep; 2017 May; 19(5):36. PubMed ID: 28417343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas.
    Thomé SD; Loprinzi CL; Heldebrant MP
    Mayo Clin Proc; 2002 Sep; 77(9):913-7. PubMed ID: 12233924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Building upon the standard of care in adjuvant therapy of high-risk melanoma.
    Kirkwood JM
    J Clin Oncol; 2005 Dec; 23(34):8559-63. PubMed ID: 16260699
    [No Abstract]   [Full Text] [Related]  

  • 28. Adjuvant therapy for melanoma.
    Sondak VK
    Cancer J; 2001; 7 Suppl 1():S24-7. PubMed ID: 11504282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.
    Kaehler KC; Blome C; Forschner A; Gutzmer R; Haalck T; Heinzerling L; Kornek T; Livingstone E; Loquai C; Maul LV; Lang BM; Schadendorf D; Stade B; Terheyden P; Utikal J; Wagner T; Hauschild A; Garbe C; Augustin M
    Medicine (Baltimore); 2016 Nov; 95(46):e5375. PubMed ID: 27861370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
    Kaehler KC; Sondak VK; Schadendorf D; Hauschild A
    Eur J Cancer; 2010 Jan; 46(1):41-6. PubMed ID: 19857957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
    Groenewegen G; Osanto S; van der Rhee HJ; Punt CJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2160-2. PubMed ID: 11086492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of interferon in melanoma patients: a systematic review.
    Di Trolio R; Simeone E; Di Lorenzo G; Buonerba C; Ascierto PA
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):203-12. PubMed ID: 25511547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant high-dose interferon revisited.
    Sondak VK; Flaherty LE
    Cancer J; 2000; 6(3):132-4. PubMed ID: 10882326
    [No Abstract]   [Full Text] [Related]  

  • 34. [Interferon for adjuvant therapy of melanoma: approved, not indicated].
    Croockewit AJ; Koopmans PP; Lekkerkerker JF
    Ned Tijdschr Geneeskd; 2001 Mar; 145(10):498-9. PubMed ID: 11268915
    [No Abstract]   [Full Text] [Related]  

  • 35. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
    Wang E; Zhao Y; Monaco A; Uccellini L; Kirkwood JM; Spyropoulou-Vlachou M; Panelli MC; Marincola FM; Gogas H
    PLoS One; 2012; 7(7):e40805. PubMed ID: 22911710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
    D'Aniello C; Perri F; Scarpati GDV; Pepa CD; Pisconti S; Montesarchio V; Wernert N; Zarone MR; Caraglia M; Facchini G; Berretta M; Cavaliere C
    Curr Cancer Drug Targets; 2018; 18(5):442-456. PubMed ID: 28183255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Melanoma: a new interferon is coming ... handle with care!].
    Négrier S
    Bull Cancer; 1997 Apr; 84(4):435-7. PubMed ID: 9238171
    [No Abstract]   [Full Text] [Related]  

  • 38. Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b.
    Hurley KE; Chapman PB
    Oncologist; 2005 Oct; 10(9):739-42. PubMed ID: 16249355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermatomyositis after interferon alpha treatment.
    Dietrich LL; Bridges AJ; Albertini MR
    Med Oncol; 2000 Feb; 17(1):64-9. PubMed ID: 10713663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon alfa-2a for melanoma metastases.
    Kirkwood JM; Ibrahim JG; Sondak VK; Ernstoff MS; Ross M
    Lancet; 2002 Mar; 359(9310):978-9. PubMed ID: 11918944
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.